120 related articles for article (PubMed ID: 6265342)
21. A blinded comparison of noninvasive, in vivo phosphorus nuclear magnetic resonance spectroscopy and the in vitro halothane/caffeine contracture test in the evaluation of malignant hyperthermia susceptibility.
Olgin J; Rosenberg H; Allen G; Seestedt R; Chance B
Anesth Analg; 1991 Jan; 72(1):36-47. PubMed ID: 1984374
[TBL] [Abstract][Full Text] [Related]
22. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
Ording H; Bendixen D
Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
[TBL] [Abstract][Full Text] [Related]
23. Prediction of malignant hyperthermia susceptibility in low-risk subjects. An epidemiologic investigation of caffeine halothane contracture responses. The North American Malignant Hyperthermia Registry.
Larach MG; Landis JR; Bunn JS; Diaz M
Anesthesiology; 1992 Jan; 76(1):16-27. PubMed ID: 1729931
[TBL] [Abstract][Full Text] [Related]
24. Is the "K-type" caffeine-halothane responder susceptible to malignant hyperthermia?
Ellis FR; Halsall PJ; Hopkins PM
Br J Anaesth; 1992 Nov; 69(5):468-70. PubMed ID: 1467078
[TBL] [Abstract][Full Text] [Related]
25. Ca(2+)-ATPase and Na(+)-K(+)-ATPase content in skeletal muscle from malignant hyperthermia patients.
Everts ME; Ording H; Hansen O; Nielsen PA
Muscle Nerve; 1992 Feb; 15(2):162-7. PubMed ID: 1312675
[TBL] [Abstract][Full Text] [Related]
26. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met.
Rueffert H; Wehner M; Ogunlade V; Meinecke C; Schober R
Clin Neuropathol; 2009; 28(6):409-16. PubMed ID: 19919814
[TBL] [Abstract][Full Text] [Related]
27. Cystathionine β-synthase-derived hydrogen sulfide is involved in human malignant hyperthermia.
Vellecco V; Mancini A; Ianaro A; Calderone V; Attanasio C; Cantalupo A; Andria B; Savoia G; Panza E; Di Martino A; Cirino G; Bucci M
Clin Sci (Lond); 2016 Jan; 130(1):35-44. PubMed ID: 26460077
[TBL] [Abstract][Full Text] [Related]
28. [Diagnosis of susceptibility for malignant hyperthermia using in-vitro muscle contraction testing in Switzerland].
Urwyler A; Censier K; Seeberger MD; Drewe J; Rothenbühler JM; Frei F
Schweiz Med Wochenschr; 1991 Apr; 121(16):566-71. PubMed ID: 2042040
[TBL] [Abstract][Full Text] [Related]
29. Effects of ryanodine on skeletal muscle lactate and pyruvate in malignant hyperthermia-susceptible and normal swine as assessed by microdialysis.
Bina S; Muldoon S; Bünger R
Eur J Anaesthesiol; 2008 Jan; 25(1):48-57. PubMed ID: 17686208
[TBL] [Abstract][Full Text] [Related]
30. A comparison of the caffeine halothane muscle contracture test with the molecular genetic diagnosis of malignant hyperthermia.
MacKenzie AE; Allen G; Lahey D; Crossan ML; Nolan K; Mettler G; Worton RG; MacLennan DH; Korneluk R
Anesthesiology; 1991 Jul; 75(1):4-8. PubMed ID: 2064058
[TBL] [Abstract][Full Text] [Related]
31. Increased skeletal muscle acetylcholinesterase activity in porcine malignant hyperthermia.
Mickelson JR; Thatte HS; Beaudry TM; Gallant EM; Louis CF
Muscle Nerve; 1987 Oct; 10(8):723-7. PubMed ID: 3683445
[TBL] [Abstract][Full Text] [Related]
32. Effects of caffeine, halothane, and 4-chloro-m-cresol on skeletal muscle lactate and pyruvate in malignant hyperthermia-susceptible and normal swine as assessed by microdialysis.
Bina S; Cowan G; Karaian J; Muldoon S; Mongan P; Bünger R
Anesthesiology; 2006 Jan; 104(1):90-100. PubMed ID: 16394695
[TBL] [Abstract][Full Text] [Related]
33. Results of contracture tests with halothane, caffeine, and ryanodine depend on different malignant hyperthermia-associated ryanodine receptor gene mutations.
Fiege M; Wappler F; Weisshorn R; Ulrich Gerbershagen M; Steinfath M; Schulte Am Esch J
Anesthesiology; 2002 Aug; 97(2):345-50. PubMed ID: 12151923
[TBL] [Abstract][Full Text] [Related]
34. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests].
Mortier W; Breucking E
Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201
[TBL] [Abstract][Full Text] [Related]
35. Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels.
Weglinski MR; Wedel DJ; Engel AG
Anesth Analg; 1997 May; 84(5):1038-41. PubMed ID: 9141928
[TBL] [Abstract][Full Text] [Related]
36. [Central core disease associated with malignant hyperthermia sensitivity].
Krivosic-Horber R; Krivosic I
Presse Med; 1989 Apr; 18(16):828-31. PubMed ID: 2524766
[TBL] [Abstract][Full Text] [Related]
37. Levels of adenylate deaminase, adenylate kinase, and creatine kinase in frozen human muscle biopsy specimens relative to type 1/type 2 fiber distribution: evidence for a carrier state of myoadenylate deaminase deficiency.
Fishbein WN; Armbrustmacher VW; Griffin JL; Davis JI; Foster WD
Ann Neurol; 1984 Mar; 15(3):271-7. PubMed ID: 6326659
[TBL] [Abstract][Full Text] [Related]
38. No relationship between fiber type and halothane contracture test results in malignant hyperthermia.
Heiman-Patterson T; Fletcher JE; Rosenberg H; Tahmoush AJ
Anesthesiology; 1987 Jul; 67(1):82-4. PubMed ID: 2440353
[TBL] [Abstract][Full Text] [Related]
39. Masseter muscle rigidity and malignant hyperthermia susceptibility.
Rosenberg H; Fletcher JE
Anesth Analg; 1986 Feb; 65(2):161-4. PubMed ID: 3942303
[TBL] [Abstract][Full Text] [Related]
40. Serum creatine kinase level as a screening test for susceptibility to malignant hyperthermia.
Paasuke RT; Brownell AK
JAMA; 1986 Feb; 255(6):769-71. PubMed ID: 3944979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
